Overview

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The safety, tolerability and recommended phase 2 dose (RP2D) of the combination of gefitinib and BKM120 will be determined.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
Novartis
Treatments:
Gefitinib